Shah, Anita
Solms, Alexander
Wiegmann, Sara
Ahsman, Maurice
Berntorp, Erik
Tiede, Andreas
Iorio, Alfonso
Mancuso, Maria Elisa
Zhivkov, Tihomir
Lissitchkov, Toshko
Funding for this research was provided by:
Bayer HealthCare
Article History
Received: 14 February 2019
Accepted: 15 June 2019
First Online: 24 June 2019
Compliance with ethical standards
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was provided by the patients, and the protocol was approved by the single site’s independent Ethics Committee/Institutional Review Board.
: Anita Shah, Alexander Solms, and Sara Wiegmann are employees of Bayer. Maurice Ahsman is an employee of LAP&P Consultants BV, working for Bayer. Anita Shah and Alexander Solms are also shareholders of Bayer. Erik Berntorp is a consultant for Bayer, LFB, Octapharma, Roche, and Shire; is a Speaker Bureau member for Bayer; and has received research support from Bayer, CSL Behring, Shire, and Sobi/Bioverativ. Andreas Tiede has received research grants and personal fees for lectures and consultancy from Alnylam, Bayer, Biogen Idec, Biotest, Boehringer Ingelheim, Chugai, CSL Behring, Daiichi Sankyo, Leo Pharma, Novo Nordisk, Octapharma, Pfizer, Portola, Roche, Shire, and Sobi. Alfonso Iorio’s institution has received grants/research support from Bayer, CSL, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, and Shire. Maria Elisa Mancuso is a consultant for Bayer, CSL Behring, Novo Nordisk, Roche, Pfizer, Baxalta/Shire, Kedrion, and Catalyst, and a Speaker Bureau member for Bayer, CSL Behring, Novo Nordisk, Roche, Baxalta/Shire, Biotest, and Octapharma. Toshko Lissitchkov is a shareholder of Bayer, Sobi, Octapharma, Roche, Sanofi, and Shire; has received grants/research support from Bayer, Octapharma, and Sanofi; is a consultant for Bayer, Sobi, Roche, and Shire; is a Speaker Bureau member for Roche and Shire; and has received from the company financial support as a principal investigator of clinical trials. Tihomir Zhivkov has nothing to declare.